Fauna Bio is an innovative biotechnology company that leverages evolutionary biology and artificial intelligence to drive drug discovery. By studying the genetic data of various mammals, Fauna Bio aims to unlock mechanisms of natural disease resistance that have evolved over 100 million years. Their proprietary platform, Convergence™, allows for the identification of druggable targets across a wide range of diseases, including obesity, neurodegeneration, and heart failure. The company utilizes a unique biobank of genetic data and comparative genomics to inform their research, significantly reducing the costs and time typically associated with drug development.

The company focuses on extreme animal models, such as the 13-lined ground squirrel and spiny mice, which exhibit remarkable metabolic adaptations and regenerative capabilities. These species provide insights into potential therapeutic targets that can be translated into human medicine. Fauna Bio's collaborations with academic institutions and partnerships with major pharmaceutical companies, like Eli Lilly, further enhance their research capabilities and market potential. By integrating vast datasets from animal genomes with human genomic data, Fauna Bio is positioned to create novel therapeutic solutions that address some of humanity's most pressing health challenges.

United States

Fauna Bio is inspired by the untapped potential of non-model organism biology.  We leverage insights from extraordinary mammalian phenotypes to develop novel translational therapeutics for disease prevention and reduce the impact of age-related diseases in humans.

Fauna Bio

Company Details